Federal Circuit Confirms Patent Eligibility of Gene Therapy Patent in Regenexbio Inc. v. Sarepta Therapeutics
Key Takeaway: Genetically engineered cultured host cells containing recombinant nucleic acids useful for gene therapy are patent-eligible for being markedly different from anything occurring in nature. In REGENXBIO Inc. v....
USPTO Director Signals Continued Pro-Patent Discretionary Denial Policy at the Patent Trial and Appeal Board
Key Takeaway: In a precedential decision in Magnolia Medical Technologies, Inc. v. Kurin, Inc., USPTO Director Squires denied IPR institution and reinforced the policy framework for discretionary denial at the...
eVTOL Takes Flight: Navigating Certification, Regulation, and IP in Advanced Air Mobility
Key Takeaways: eVTOL aircraft are moving toward real-world deployment, but certification remains a critical hurdle alongside early operational programs like the FAA’s eIPP. As companies advance in parallel, careful coordination...
Subscribe for News and Updates
